Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
Data from a small study at the University of California at San Francisco suggest that magnetic resonance (MR) spectroscopic imaging is better than T2-weighted MR imaging alone for the detection of locally recurrent prostate cancer after definitive external beam radiation therapy (EBRT) as first-line therapy.
Filed under: Management, Treatment | Tagged: detection, magentic resonance imaging, MRI, recurrence | Leave a Comment »
There’s an article in today’s Wall Street Journal that begins, “Scientists may soon be able to answer the agonizing question facing men with prostate cancer.” The agonizing question is whether a specific individual actually needs early and aggressive treatment for his cancer or can simply monitor it for risk of progression.
Filed under: Diagnosis, Management, Risk | Tagged: classification, genetics, profiling, progression, risk | 3 Comments »
For all of the academic literature and the recommendations of guideline-generating organizations on testing, diagnosis, and management of prostate cancer, urologists out in community practice may show considerable variation in their clinical practice patterns.
Filed under: Diagnosis, Risk | Tagged: biopsy, Canadian, patterns, practice, PSA, urologist | 7 Comments »
According to a report on Bloomberg Businessweek earlier today, “rationing” of sipuleucel-T (Provenge), the new cellular immunotherapeutic agent approved for treatment of metastatic, castration-resistant prostate cancer, has already become evident.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: capacity, Provenge, sipuleucel-T | Leave a Comment »
According to a media release from Duke Comprehensive Cancer Center, patients who take a statin after receiving a radical prostatectomy as first-line therapy for prostate cancer are at lower risk for a rising PSA after treatment than men who are not on statin therapy.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: outcome, progression, radical prostatectomy, statin | 2 Comments »
A new epidemiological analysis of data from Denmark, Finland, Norway, and Sweden suggests that despite a significant increase in the incidence of prostate cancer (the number of men diagnosed each year), prostate cancer-specific mortality rates have been minimally affected over the past 40 years in these four countries.
Filed under: Diagnosis, Risk | Tagged: incidence, mortality, risk, Scandinavia | 6 Comments »
We know from prior studies that recurrence of prostate cancer after a radical prostatectomy is related to tumor biology and to surgical surgical skill and experience, but is one more important than the other?
Filed under: Management, Treatment | Tagged: biology, experience, outcome, recurrence, skill, surgery | 5 Comments »
New data from a research team at the Institute for Cancer Research in the UK suggest that — in men and women with a faulty BRCA2 gene — the development of breast cancer and prostate cancer follows a similar pathway.
Filed under: Uncategorized | Tagged: BRCA2, gene | Leave a Comment »
Earlier today, an interdepartmental research team from Memorial Sloan-Kettering Cancer Center in New York published the most comprehensive genomic prostate cancer database available to date.
Filed under: Diagnosis, Drugs in development | Tagged: database, genomic | 3 Comments »
The potential of “natural products” as agents to prevent and/or treat prostate cancer (and other forms of cancer) is a topic of constant interest to many patients — even though the available data has demonstrated — at best — a limited effectiveness of almost all such products tested.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: anxiety, extract, mushroom, mycelium, PSA | 2 Comments »
A recently published Italian study has reported on whether perineural invasion (PNI) has prognostic value in patients undergoing radical prostatectomy for organ-confined prostate cancer, and on its possible correlation with other recognized prognostic factors.
Filed under: Management, Treatment | Tagged: Gleason score, outcome, perineural invasion, PNI, prognosis, stage | 14 Comments »
According to an article in the San Diego Union-Tribune on Monday, Scripps Health has partnered with others to develop a new proton beam radiation therapy center in San Diego. This would be the second PBRT center on the West Coast and supposedly it will be able to treat its first patients in 2013.
Filed under: Management | Tagged: PBRT, proton beam radiation therapy | Comments Off
From 1973 to 1993 the estrogenic insecticide chlordecone (marketed as Kepone) was widely used in the French West Indies to control pests in the banana crop. In the USA it was once used to bait household insect traps.
Filed under: Diagnosis, Risk | Tagged: chlordecone, estrogen, insecticide, risk | Leave a Comment »
Making predictions about the future tends to be a risky business, but according to a new paper by scientists at the Centers of Disease Control, the annual number of years of life lost to prostate cancer will have more than doubled by 2050.
Filed under: Living with Prostate Cancer, Management | Tagged: years of potential life lost, YPLL | 1 Comment »
OncoGenex has initiated the first of two Phase III trials of custirsen sodium (OGX-011) in the treatment of men with metastatic castrate-resistant prostate cancer (mCPRC).
Filed under: Drugs in development, Uncategorized | Tagged: castration-resistant, custirsen, mCRPC, OGX-011, OncoGenex | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site